Gastric Cancer
Conditions
Keywords
metastasis, Gastric Cancer, Lymph node, Mesogastrium
Brief summary
To investigate the impact of the number of mesogastria containing metastatic lymph nodes on the prognosis of gastric cancer.
Detailed description
Previous studies have established the existence of the mesogastrium, dividing it into six sections. The mesogastrium is identified during surgery and utilized in surgical practice. The aim of the present study was to further investigate its role in gastric cancer prognosis.Between January 2014 and January 2018, patients from the Tongji Hospital were included in this post-hoc analysis, including data from a randomized clinical study (DCGC01; http://www.clinicaltrials.gov, NCT01978444). Mesogastria containing metastatic lymph nodes (LNs) were referred to as metastatic mesogastria. Pathology reports were examined to assess metastases in the mesogastrium. Survival was assessed using Kaplan-Meier curves and multivariable Cox models.
Interventions
PROCEDURED2＋CME
Whether to perform the whole mesogastric excision
Sponsors
Jichao Qin
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. older than 18, younger than 85 2. primary gastric adenocarcinoma confirmed by preoperative pathology 3. routine blood tests, liver and kidney functions and who health status score are within the range of tolerable surgery 4. it is expected to perform radical gastrectomy through d2+cme
Exclusion criteria
1. pregnant or lactating women 2. severe mental disorder or language communication disorder 3. preoperative imaging examination or intraoperative exploration found that the patient had the following conditions: tumor involving surrounding organs requiring combined organ resection, distant organ metastasis or R0 resection could not be achieved 4. those who are not suitable for laparoscopic surgery (such as extensive adhesion caused by anterior abdominal surgery and pneumoperitoneum for various reasons). 5. concurrent malignancies at other sites 6. emergency surgery patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Postoperative 5-year survival | Postoperative 5-year survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Mesogastria Containing Metastatic Lymph Nodes | Postoperative 5-year | The Number of Mesogastria Containing Metastatic Lymph Nodes |
Countries
China
Outcome results
None listed